The Rising Threat of Nontuberculous Mycobacterial Lung Infections in Singapore
Singapore has witnessed a significant shift in its infectious disease landscape, with nontuberculous mycobacteria (NTM) pulmonary infections surging to levels nearly matching tuberculosis (TB). Over the past two decades, pulmonary NTM incidence has doubled, driven largely by Mycobacterium abscessus (M. abscessus), which now accounts for approximately 30% of NTM lung cases in the city-state. This opportunistic pathogen poses a formidable challenge, particularly for vulnerable populations such as those with pre-existing lung conditions like bronchiectasis or cystic fibrosis. As TB rates decline, NTM emerges as the new dominant mycobacterial threat, underscoring the urgency for innovative therapeutic strategies.
In this context, researchers at Nanyang Technological University (NTU) Singapore have delivered a groundbreaking advancement. Their cryo-electron microscopy (cryo-EM) structure of the M. abscessus cytochrome bcc:aa3 oxidase supercomplex has not only illuminated critical structural features but also paved the way for a novel QcrB inhibitor, ND-011458, targeting drug-resistant lung infections.
Understanding Mycobacterium abscessus: A Formidable Opportunistic Pathogen
Mycobacterium abscessus belongs to the Mycobacterium abscessus complex (MABC), a group of rapidly growing nontuberculous mycobacteria notorious for causing chronic pulmonary diseases. Unlike M. tuberculosis, which spreads person-to-person, M. abscessus is acquired from environmental sources such as water and soil, thriving in immunocompromised hosts. It manifests as persistent cough, hemoptysis, fatigue, and progressive lung damage, often mimicking TB but resisting standard diagnostics and treatments.
Globally, NTM pulmonary disease (NTM-PD) incidence is climbing, with cure rates hovering between 40% and 50% under current regimens—comparable to or worse than extensively drug-resistant TB. In Singapore, M. abscessus dominance in NTM isolates (up to 50% in some studies) highlights its epidemiological shift, fueled by an aging population and rising chronic lung diseases.
Current Treatment Challenges and the Need for New Targets
Treatment of M. abscessus pulmonary disease demands 12–18 months of multi-drug therapy, typically involving macrolides (e.g., clarithromycin), aminoglycosides (amikacin), beta-lactams (imipenem), and sometimes clofazimine or tigecycline. Sputum culture conversion rates range from 29–77%, with radiographic improvement in only 33–54% of cases. Adverse events like ototoxicity and hepatotoxicity lead to high discontinuation rates (up to 12.8%).
Intrinsic resistance mechanisms—efflux pumps, inducible erm(41) gene, and polymorphisms in drug targets—render many antibiotics ineffective. QcrB inhibitors like telacebec (Q203), promising against TB, fail against M. abscessus due to natural QcrB variants. This gap necessitated NTU's structural approach to redesign inhibitors for this pathogen.
The Crucial Role of Cytochrome Oxidases in Mycobacterial Survival
Mycobacteria rely on branched respiratory chains for energy via oxidative phosphorylation, adapting to hypoxic lung environments. The cytochrome bcc:aa3 oxidase supercomplex couples quinol oxidation to oxygen reduction, generating proton motive force for ATP synthesis. Targeting this terminal oxidase disrupts respiration, bactericidal under low-oxygen conditions akin to infected lungs.
In M. abscessus, dual oxidases (bd and bcc:aa3) confer resilience. While bd structures exist, the bcc:aa3 supercomplex—conserved across mycobacteria but varying in quinol-binding pockets—remained unresolved until NTU's work.
NTU's Cryo-EM Milestone: Unveiling the Supercomplex Structure
Led by Professor Gerhard Grüber and Dr. Kevin Pethe, NTU's team at the School of Biological Sciences and Lee Kong Chian School of Medicine resolved the 2.6 Å cryo-EM structure of the M. abscessus bcc:aa3 supercomplex (PDB pending, EMDB forthcoming). Utilizing NTU's state-of-the-art cryo-EM facility and collaborations with NUS, they captured the enzyme in near-native state, revealing intricate electron transfer pathways and proton conduits via Grotthuss mechanism.
This marks the first atomic view of M. abscessus bcc:aa3, contrasting with TB homologs and explaining resistance profiles.
Structural Revelations: Proton Pathways and QcrB Evolution
The structure discloses a refined menaquinol-binding cavity in QcrB, evolved for mycobacterial specificity. Key polymorphisms—naturally occurring in M. abscessus—sterically hinder telacebec binding, confirmed via site-directed mutagenesis in M. abscessus and M. smegmatis. These variants modulate potency, guiding rational design.
Proton pathways link Rieske iron-sulfur protein to aa3 domains, essential for ATP homeostasis. Inhibitor-bound cryo-EM at 2.26 Å (with ND-011458) pinpoints binding pose, optimizing future analogs. Read the full study here.
Birth of ND-011458: A Tailored QcrB Inhibitor
Exploiting structural insights, collaborators at Montana State University synthesized ND-011458, optimizing for M. abscessus QcrB pocket. It exhibits potent bacteriostatic activity, synergizing bactericidally with clofazimine—a frontline drug—disrupting respiration comprehensively. Unlike telacebec, ND-011458 evades polymorphisms, promising shorter, less toxic regimens.
Preclinical data suggest efficacy against clinical isolates, addressing a critical unmet need.
Clinical Promise: Transforming Mab Lung Disease Management
For Singapore's rising NTM burden, ND-011458 could boost cure rates beyond 50%, reducing reliance on toxic injectables. Combined with surgery (enhancing SCC to 76.9%), it offers hope for refractory cases. Globally, as NTM-PD affects millions, this inhibitor framework accelerates drug pipelines. Explore treatment outcomes review.
NTU's Structural Biology Prowess Driving Infectious Disease Research
NTU's Institute of Structural Biology (NISB), equipped with cutting-edge cryo-EM platforms, positions Singapore as a cryo-EM hub. Past feats include Zika NS1 and HMPV structures. This Mab work exemplifies NTU's translation from structure to therapeutics, bolstered by NRF funding.
Stakeholder Perspectives and Broader Impacts
Clinicians hail the advance for targeting energy metabolism, evading efflux. Patients stand to gain from oral regimens minimizing hospitalization. Pharma eyes partnerships for lead optimization. In Singapore, aligning with Smart Nation's health tech, NTU fosters academia-industry synergy.
Future Outlook: Next-Generation Inhibitors and Beyond
ND-011458 sets the stage for series expansion, combo trials, and bd oxidase targeting. NTU's pipeline promises holistic Mab attack. As NTM surges, this breakthrough reinforces Singapore's leadership in antimicrobial R&D, potentially curbing a global crisis.
